Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
© 2023 The Authors..
Objective: To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently better in identifying the need for monoclonal antibody infusion throughout each "wave" of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant predominance during the coronavirus disease 2019 (COVID-19) pandemic and that the infusion of contemporary monoclonal antibody treatments is associated with a lower risk of hospitalization.
Patients and Methods: In this retrospective cohort study, we evaluated the efficacy of monoclonal antibody treatment compared with that of no monoclonal antibody treatment in symptomatic adults who tested positive for SARS-CoV-2 regardless of their risk factors for disease progression or vaccination status during different periods of SARS-CoV-2 variant predominance. The primary outcome was hospitalization within 28 days after COVID-19 diagnosis. The study was conducted on patients with a diagnosis of COVID-19 from November 19, 2020, through May 12, 2022.
Results: Of the included 118,936 eligible patients, hospitalization within 28 days of COVID-19 diagnosis occurred in 2.52% (456/18,090) of patients who received monoclonal antibody treatment and 6.98% (7,037/100,846) of patients who did not. Treatment with monoclonal antibody therapies was associated with a lower risk of hospitalization when using stratified data analytics, propensity scoring, and regression and machine learning models with and without adjustments for putative confounding variables, such as advanced age and coexisting medical conditions (eg, relative risk, 0.15; 95% CI, 0.14-0.17).
Conclusion: Among patients with mild to moderate COVID-19, including those who have been vaccinated, monoclonal antibody treatment was associated with a lower risk of hospital admission during each wave of the COVID-19 pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Mayo Clinic proceedings. Innovations, quality & outcomes - 7(2023), 2 vom: 30. Apr., Seite 109-121 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 06.03.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.mayocpiqo.2022.12.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351554882 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351554882 | ||
| 003 | DE-627 | ||
| 005 | 20231226051643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mayocpiqo.2022.12.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351554882 | ||
| 035 | |a (NLM)36644593 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Johnson, Patrick W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Objective: To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently better in identifying the need for monoclonal antibody infusion throughout each "wave" of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant predominance during the coronavirus disease 2019 (COVID-19) pandemic and that the infusion of contemporary monoclonal antibody treatments is associated with a lower risk of hospitalization | ||
| 520 | |a Patients and Methods: In this retrospective cohort study, we evaluated the efficacy of monoclonal antibody treatment compared with that of no monoclonal antibody treatment in symptomatic adults who tested positive for SARS-CoV-2 regardless of their risk factors for disease progression or vaccination status during different periods of SARS-CoV-2 variant predominance. The primary outcome was hospitalization within 28 days after COVID-19 diagnosis. The study was conducted on patients with a diagnosis of COVID-19 from November 19, 2020, through May 12, 2022 | ||
| 520 | |a Results: Of the included 118,936 eligible patients, hospitalization within 28 days of COVID-19 diagnosis occurred in 2.52% (456/18,090) of patients who received monoclonal antibody treatment and 6.98% (7,037/100,846) of patients who did not. Treatment with monoclonal antibody therapies was associated with a lower risk of hospitalization when using stratified data analytics, propensity scoring, and regression and machine learning models with and without adjustments for putative confounding variables, such as advanced age and coexisting medical conditions (eg, relative risk, 0.15; 95% CI, 0.14-0.17) | ||
| 520 | |a Conclusion: Among patients with mild to moderate COVID-19, including those who have been vaccinated, monoclonal antibody treatment was associated with a lower risk of hospital admission during each wave of the COVID-19 pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CMH, Cochran-Mantel-Haenszel | |
| 650 | 4 | |a COVID-19, coronavirus disease 2019 | |
| 650 | 4 | |a EHR, electronic health record | |
| 650 | 4 | |a GBM, gradient boosting machine | |
| 650 | 4 | |a MASS, Monoclonal Antibody Screening Score | |
| 650 | 4 | |a RR, relative risk | |
| 650 | 4 | |a SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 | |
| 700 | 1 | |a Kunze, Katie L |e verfasserin |4 aut | |
| 700 | 1 | |a Senefeld, Jonathon W |e verfasserin |4 aut | |
| 700 | 1 | |a Sinclair, Jorge E |e verfasserin |4 aut | |
| 700 | 1 | |a Isha, Shahin |e verfasserin |4 aut | |
| 700 | 1 | |a Satashia, Parthkumar H |e verfasserin |4 aut | |
| 700 | 1 | |a Bhakta, Shivang |e verfasserin |4 aut | |
| 700 | 1 | |a Cowart, Jennifer B |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Wendelyn |e verfasserin |4 aut | |
| 700 | 1 | |a O'Horo, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Sadia Z |e verfasserin |4 aut | |
| 700 | 1 | |a Wadei, Hani M |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, Benjamin D |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Alana J |e verfasserin |4 aut | |
| 700 | 1 | |a Scheitel-Tulledge, Sidna |e verfasserin |4 aut | |
| 700 | 1 | |a Clune, Caroline G |e verfasserin |4 aut | |
| 700 | 1 | |a Hanson, Sara N |e verfasserin |4 aut | |
| 700 | 1 | |a Arndt, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Heyliger, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Kudrna, Cory |e verfasserin |4 aut | |
| 700 | 1 | |a Bierle, Dennis M |e verfasserin |4 aut | |
| 700 | 1 | |a Buckmeier, Jason R |e verfasserin |4 aut | |
| 700 | 1 | |a Seville, Maria Teresa A |e verfasserin |4 aut | |
| 700 | 1 | |a Orenstein, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Libertin, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Ganesh, Ravindra |e verfasserin |4 aut | |
| 700 | 1 | |a Franco, Pablo Moreno |e verfasserin |4 aut | |
| 700 | 1 | |a Razonable, Raymund R |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Rickey E |e verfasserin |4 aut | |
| 700 | 1 | |a Sanghavi, Devang K |e verfasserin |4 aut | |
| 700 | 1 | |a Speicher, Leigh L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mayo Clinic proceedings. Innovations, quality & outcomes |d 2017 |g 7(2023), 2 vom: 30. Apr., Seite 109-121 |w (DE-627)NLM286756471 |x 2542-4548 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:2 |g day:30 |g month:04 |g pages:109-121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mayocpiqo.2022.12.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 2 |b 30 |c 04 |h 109-121 | ||